PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
FINV vs. ASND
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between FINV and ASND is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.2

Performance

FINV vs. ASND - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in FinVolution Group (FINV) and Ascendis Pharma A/S (ASND). The values are adjusted to include any dividend payments, if applicable.

0.00%100.00%200.00%300.00%400.00%NovemberDecember2025FebruaryMarchApril
-22.92%
356.82%
FINV
ASND

Key characteristics

Sharpe Ratio

FINV:

1.40

ASND:

0.36

Sortino Ratio

FINV:

2.07

ASND:

0.95

Omega Ratio

FINV:

1.27

ASND:

1.11

Calmar Ratio

FINV:

1.11

ASND:

0.44

Martin Ratio

FINV:

6.57

ASND:

1.44

Ulcer Index

FINV:

8.79%

ASND:

11.58%

Daily Std Dev

FINV:

41.26%

ASND:

46.06%

Max Drawdown

FINV:

-89.64%

ASND:

-61.72%

Current Drawdown

FINV:

-30.69%

ASND:

-9.69%

Fundamentals

Market Cap

FINV:

$1.87B

ASND:

$9.51B

EPS

FINV:

$1.24

ASND:

-$7.40

PS Ratio

FINV:

0.14

ASND:

26.15

PB Ratio

FINV:

0.95

ASND:

14.55

Total Revenue (TTM)

FINV:

$9.90B

ASND:

$267.75M

Gross Profit (TTM)

FINV:

$7.99B

ASND:

$231.06M

EBITDA (TTM)

FINV:

$2.99B

ASND:

-$109.02M

Returns By Period

In the year-to-date period, FINV achieves a 9.43% return, which is significantly lower than ASND's 19.89% return.


FINV

YTD

9.43%

1M

-30.69%

6M

29.45%

1Y

58.77%

5Y*

40.13%

10Y*

N/A

ASND

YTD

19.89%

1M

0.24%

6M

30.31%

1Y

16.09%

5Y*

5.06%

10Y*

23.69%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

FINV vs. ASND — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

FINV
The Risk-Adjusted Performance Rank of FINV is 8989
Overall Rank
The Sharpe Ratio Rank of FINV is 9191
Sharpe Ratio Rank
The Sortino Ratio Rank of FINV is 8888
Sortino Ratio Rank
The Omega Ratio Rank of FINV is 8686
Omega Ratio Rank
The Calmar Ratio Rank of FINV is 8787
Calmar Ratio Rank
The Martin Ratio Rank of FINV is 9191
Martin Ratio Rank

ASND
The Risk-Adjusted Performance Rank of ASND is 6868
Overall Rank
The Sharpe Ratio Rank of ASND is 6969
Sharpe Ratio Rank
The Sortino Ratio Rank of ASND is 6767
Sortino Ratio Rank
The Omega Ratio Rank of ASND is 6262
Omega Ratio Rank
The Calmar Ratio Rank of ASND is 7373
Calmar Ratio Rank
The Martin Ratio Rank of ASND is 7070
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

FINV vs. ASND - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for FinVolution Group (FINV) and Ascendis Pharma A/S (ASND). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for FINV, currently valued at 1.40, compared to the broader market-2.00-1.000.001.002.003.00
FINV: 1.40
ASND: 0.36
The chart of Sortino ratio for FINV, currently valued at 2.07, compared to the broader market-6.00-4.00-2.000.002.004.00
FINV: 2.07
ASND: 0.95
The chart of Omega ratio for FINV, currently valued at 1.27, compared to the broader market0.501.001.502.00
FINV: 1.27
ASND: 1.11
The chart of Calmar ratio for FINV, currently valued at 1.11, compared to the broader market0.001.002.003.004.00
FINV: 1.11
ASND: 0.44
The chart of Martin ratio for FINV, currently valued at 6.57, compared to the broader market-5.000.005.0010.0015.0020.00
FINV: 6.57
ASND: 1.44

The current FINV Sharpe Ratio is 1.40, which is higher than the ASND Sharpe Ratio of 0.36. The chart below compares the historical Sharpe Ratios of FINV and ASND, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.00NovemberDecember2025FebruaryMarchApril
1.40
0.36
FINV
ASND

Dividends

FINV vs. ASND - Dividend Comparison

FINV's dividend yield for the trailing twelve months is around 3.87%, while ASND has not paid dividends to shareholders.


TTM202420232022202120202019
FINV
FinVolution Group
3.87%3.49%4.39%4.13%3.45%4.49%7.17%
ASND
Ascendis Pharma A/S
0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Drawdowns

FINV vs. ASND - Drawdown Comparison

The maximum FINV drawdown since its inception was -89.64%, which is greater than ASND's maximum drawdown of -61.72%. Use the drawdown chart below to compare losses from any high point for FINV and ASND. For additional features, visit the drawdowns tool.


-40.00%-30.00%-20.00%-10.00%0.00%NovemberDecember2025FebruaryMarchApril
-30.69%
-9.69%
FINV
ASND

Volatility

FINV vs. ASND - Volatility Comparison

FinVolution Group (FINV) has a higher volatility of 18.15% compared to Ascendis Pharma A/S (ASND) at 12.71%. This indicates that FINV's price experiences larger fluctuations and is considered to be riskier than ASND based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%NovemberDecember2025FebruaryMarchApril
18.15%
12.71%
FINV
ASND

Financials

FINV vs. ASND - Financials Comparison

This section allows you to compare key financial metrics between FinVolution Group and Ascendis Pharma A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab